RT Journal Article
SR Electronic
T1 Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.03.22271313
DO 10.1101/2022.03.03.22271313
A1 Puga-Gómez, Rinaldo
A1 Ricardo-Delgado, Yariset
A1 Rojas-Iriarte, Chaumey
A1 Céspedes-Henriquez, Leyanis
A1 Piedra-Bello, Misleidys
A1 Vega-Mendoza, Dania
A1 Pérez, Noelvia Pestana
A1 Paredes-Moreno, Beatriz
A1 Rodríguez-González, Meiby
A1 Valenzuela-Silva, Carmen
A1 Sánchez-Ramírez, Belinda
A1 Rodríguez-Noda, Laura
A1 Pérez-Nicado, Rocmira
A1 González-Mugica, Raul
A1 Hernández-García, Tays
A1 Fundora-Barrios, Talía
A1 Echevarría, Martha Dubet
A1 Enriquez-Puertas, Juliet María
A1 Hernández, Yenicet Infante
A1 Palenzuela-Díaz, Ariel
A1 Gato-Orozco, Evelyn
A1 Chappi-Estévez, Yanet
A1 Francisco-Pérez, Julio Cesar
A1 Martinez, Miladi Suarez
A1 Castillo-Quintana, Ismavy C.
A1 Fernandez-Castillo, Sonsire
A1 Climent-Ruiz, Yanet
A1 Santana-Mederos, Darielys
A1 García-Vega, Yanelda
A1 Toledo-Romani, María Eugenia
A1 Valdés-Balbín, Yury
A1 García-Rivera, Dagmar
A1 Vérez-Bencomo, Vicente
A1 SOBERANA Research Group
YR 2022
UL http://medrxiv.org/content/early/2022/03/06/2022.03.03.22271313.abstract
AB Objectives To evaluate heterologous scheme in children 3-18 y/o using two SARS-CoV-2 r-RBD protein vaccines.Methods A phase I/II open-label, adaptive and multicenter trial evaluated the safety and immunogenicity of two doses of SOBERANA02 and a heterologous third dose of SOBERANA Plus in 350 children 3-18 y/o in Havana Cuba. Primary outcomes were safety (in phase I) and safety/immunogenicity (in phase II) measured by anti-RBD IgG ELISA, molecular and live-virus neutralization tests and specific T-cells response. An immunobridging and prediction of efficacy were additional analysis.Results Local pain was the unique adverse event with >10% frequency, none was serious or severe. Two doses of SOBERANA 02 elicited humoral immune response similar to natural infection; the third dose increased significantly the response in all children, similar to that achieved in vaccinated young adults and higher than in convalescents children. The neutralizing titer was evaluated in a participant’s subset: all had neutralizing antibodies vs. alpha and delta; 97.9% vs. beta. GMT was 173.8 (CI 95% 131.7; 229.5) vs. alpha, 142 (CI 95% 101.3; 198.9) vs. delta and 24.8 (CI 95% 16.8; 36.6) vs. beta. An efficacy over 90% was estimated.Conclusion Heterologous scheme was safe and immunogenic in children 3-18 y/o. Trial registry: https://rpcec.sld.cu/trials/RPCEC00000374Competing Interest StatementThe authors R.P.G, Y.R.D, C.R.I, L.C.H. M.P.B, D.V.M, N.P.P, C.V.S, A.P.D, E.G.O, Y.C.E, J.C.F.P, M.S.M, M.D.E, J.M.E.P, Y.I.H, M.E.T.R declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors B.P.M, M.R.G, B.S.R, L.M.R.N, R.P.N, R.G.M, T.H.G, T.F.B, I.C.Q, S.F.C, Y.C.R, D.S.M, Y.G.V, Y.V.B, D.G.R, V.V.B work at Finlay Vaccine Institute or the Centre of Molecular Immunology, institutions that develop and manufacture the vaccine candidates but they have not received an honorarium for this paper B.S.R., S.F.C., Y.C.R, L.R.N., D.S.M., Y.V.B., D.G.R. and V.V.B., have filed patent applications related to the vaccine SOBERANA 02. Clinical TrialRPCEC00000374Clinical Protocols https://rpcec.sld.cu/ensayos/RPCEC00000374-Sp Funding StatementThis work was supported by the Finlay Vaccine Institute, BioCubaFarma and the National Funds for Sciences and Technology from the Ministry of Science, Technology and Environment (FONCI-CITMA-Cuba, contract 2020-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Ethical Committee at the Juan Manuel Marquez Pediatric Hospital and endorsed by the Cuban National Pediatric Group.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.finlay.edu.cu/blog/category/sala-cientifica/